Skip to main content
Clinical Trials/NCT02661451
NCT02661451
Active, not recruiting
Not Applicable

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure: A Randomized Trial (TAVR UNLOAD)

Cardiovascular Research Foundation, New York51 sites in 3 countries178 target enrollmentSeptember 2016

Overview

Phase
Not Applicable
Intervention
SAPIEN 3 THV
Conditions
Aortic Valve Stenosis
Sponsor
Cardiovascular Research Foundation, New York
Enrollment
178
Locations
51
Primary Endpoint
Disabling Stroke
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate AS as compared with OHFT.

Registry
clinicaltrials.gov
Start Date
September 2016
End Date
February 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Cardiovascular Research Foundation, New York
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

TAVR (with SAPIEN 3 THV) and OHFT

Transcatheter heart valve and Optimal Heart Failure Therapy

Intervention: SAPIEN 3 THV

TAVR (with SAPIEN 3 THV) and OHFT

Transcatheter heart valve and Optimal Heart Failure Therapy

Intervention: Optimal Heart Failure Therapy

OHFT

Optimal Heart Failure Therapy

Intervention: Optimal Heart Failure Therapy

Outcomes

Primary Outcomes

Disabling Stroke

Time Frame: 12 months

Hierarchical occurrence within efficacy assessment time interval (EATI) of:

Hospitalizations related to heart failure, symptomatic aortic valve disease or non-disabling stroke -or - Clinically significant worsening of heart failure (heart failure hospitalization equivalent).

Time Frame: 12 months

Hierarchical occurrence within efficacy assessment time interval (EATI) of:

Change in KCCQ relative to baseline

Time Frame: 12 months

Hierarchical occurrence within efficacy assessment time interval (EATI) of:

All-Cause Death

Time Frame: 12 months

Hierarchical occurrence within efficacy assessment time interval (EATI) of:

Secondary Outcomes

  • -All-cause death within EATI(12 month)
  • MACCE defined as the composite of all-cause death, all stroke, and hospitalizations for heart failure or symptomatic aortic valve disease or clinically significant worsening of heart failure within EATI. Hierarchical occurrence within EATI of:(12 month)

Study Sites (51)

Loading locations...

Similar Trials